Skip to main content

Table 3 Ceramides after Myriocin treatment

From: Ceramides: a potential therapeutic target in pulmonary emphysema

Sphingolipid

Control (n=5)

Control + Myriocin (n=9)

Elastase (n=9)

Elastase + Myriocin (n=10)

Ceramide 16:0

30.01 ± 6.65

22.23 ± 7.95

41.04 ± 18.77

21.69 ± 4.91[]

Ceramide 18:0

3.13 ± 0.58

2.86 ± 0.75

4.00 ± 1.89

2.61 ± 0.60[]

Ceramide 20:0

1.94 ± 0.47

1.93 ± 0.43

2.73 ± 1.18

2.02 ± 0.43

Ceramide 22:0

7.97 ± 1.67

7.99 ± 3.42

15.13 ± 7.96*

9.11 ± 3.02[]

Ceramide 24:0

37.34 ± 9.00

33.24 ± 13.50

77.75 ± 44.65*

39.72 ± 13.00[]

Ceramide 24:1

24.66 ± 7.60

17.33 ± 8.02

41.48 ± 20.83*

19.44 ± 6.27[]

Dihydro Ceramide 18:0

0.38 ± 0.21

0.37 ± 0.20

0.70 ± 0.27*

0.44 ± 0.17[]

Dihydro Ceramide 24:0

1.97 ± 1.18

1.83 ± 0.65

6.12 ± 3.94*

3.42 ± 2.21[]

  1. BAL fluid was collected and processed using LCMS. Data are expressed as Mean + SEM in ng/ml BAL fluid. *p<0.05 when compared to Control. [] p<0.05 when compared to Elastase + Myriocin.